Cerivastatin withdrawn

To validate new methods and have them accepted by the various U.S. regulatory committees, Dr. Stitzel, along with many organizations, actively supported legislation to create a permanent agency known as the Interagency Coordinating Committee for the Validation of Alternative Methods. Dr. Stitzel served on the planning committee of the Fourth World Congress on Alternatives and Animal Use in the Life Sciences, held in August 2002. Dr. Stitzel retired in 2002 and remains an active player in the testing alternatives realm. These GPPIs can be found in the database of the Initiative on Public-Private Partnerships for Health IPPPH ; , see : ippph . According to IPPPH information, Merck would also be involved with the Viramune Donation Programme VDP ; , but this seems to be incorrect. Viramune is a drug of another pharmaceutical company, Boehrigner-Ingelheim. 84 Communication with M. Kohn, 30 September 2004. 85 Communication with S. Khalil, June 17, 2004. 86 This sections is largely based on communication with B. Colatrella on May 24, May 26, June 4 & June 25, 2004. One hundred two volunteers underwent assessment for sensitivity to tree or grass allergy; 61 met the entrance criteria and were randomly assigned to the treatment groups. Thirty-one were assigned to the desloratadine group, and 30 were assigned to the budesonide group. The demographic data did not show any significant differences between the groups Table 1 ; . All of these subjects completed the study and were included in the data analysis. The study period began on March 17, 2003, when the first volunteer underwent skin testing. Enrollment began on April 22, 2003, and pro. Given that WEB 2086 was shown to reduce strongly monocyte endothelial cell interactions in vitro, we examined its effect in vivo. Ten-week-old female C57BL 6J LDL R mice were placed on a chow diet or Western diet for 5 weeks; half of the mice received normal drinking water and half received drinking water containing WEB 2086. The animals were caged separately, and thus we could compare the amount of food and water intake by the animals. The general health and size were comparable, and no effect of WEB 2086 was observed. Previous in vivo studies from other groups32 Abstract Background. We previously reported urinary podocytes to be a marker of glomerular injury. The aim of the present study was to determine whether cerivastatin, a newly developed, potent synthetic statin, affects proteinuria and urinary podocyte excretion in patients with chronic glomerulonephritis CGN ; . Methods. We randomly assigned 40 normotensive hypercholesterolemic patients with CGN to receive either cerivastatin 0.15 mguday ns20 ; or placebo ns20 ; . Subjects comprised 24 men and 16 women, with a mean age of 40.8"14.4 years; 27 had IgA nephropathy and 13 had non-IgA proliferative glomerulonephritis. Treatment was continued for 6 months. Plasma total cholesterol, HDL-cholesterol, LDLcholesterol and triglycerides, urinary protein excretion and the number of podocytes were measured before treatment and at 3 and 6 months after treatment. Results. After 6 months, a significant reduction in total cholesterol P-0.001 ; , LDL-cholesterol P-0.001 ; and triglycerides P-0.05 ; , and a significant increase in HDL-cholesterol P-0.001 ; were observed in the group treated with cerivastatin. Urinary protein excretion decreased from 1.8"0.6 to 0.8"0.4 guday, P-0.01 ; in this group, and urinary podocyte excretion decreased from 1.6"0.6 to 0.9"0.4 cellsuml P-0.01 ; . However, placebo showed little effect on these lipid levels, urinary protein excretion and urinary podocyte excretion. The differences between the cerivastatin group and the placebo group were significant cholesterol, P-0.001; LDL-cholesterol, P-0.001; triglycerides, P-0.05; HDL-cholesterol, P-0.001; urinary protein, P-0.01; and urinary podocytes, P-0.01.